Fritz Offner
Overview
Explore the profile of Fritz Offner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
4807
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Phillips T, Carlo-Stella C, Morschhauser F, Bachy E, Crump M, Trneny M, et al.
J Clin Oncol
. 2024 Oct;
43(3):318-328.
PMID: 39365960
Purpose: Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) have a poor prognosis. The phase I/II NP30179 study (ClinicalTrials.gov identifier: NCT03075696) evaluated glofitamab monotherapy in patients with R/R B-cell lymphomas,...
2.
Decruyenaere P, Daneels W, Morlion A, Verniers K, Anckaert J, Tavernier J, et al.
Int J Mol Sci
. 2024 Sep;
25(18).
PMID: 39337470
The potential of RNA-based liquid biopsy is increasingly being recognized in diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma. This study explores the cell-free transcriptome in...
3.
Benoit D, De Pauw A, Jacobs C, Moors I, Offner F, Velghe A, et al.
Intensive Care Med
. 2024 Sep;
51(1):245-246.
PMID: 39297947
No abstract available.
4.
Benoit D, De Pauw A, Jacobs C, Moors I, Offner F, Velghe A, et al.
Intensive Care Med
. 2024 Sep;
50(10):1635-1646.
PMID: 39230678
Purpose: The aim of this study was to assess whether coaching doctors to enhance ethical decision-making in teams improves (1) goal-oriented care operationalized via written do-not-intubate and do-not attempt cardiopulmonary...
5.
Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al.
Lancet Oncol
. 2024 Jun;
25(8):1003-1014.
PMID: 38889735
Background: CASSIOPEIA part 1 demonstrated superior depth of response and prolonged progression-free survival with daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) alone...
6.
De Munter S, Buhl J, De Cock L, Van Parys A, Daneels W, Pascal E, et al.
Cancer Immunol Res
. 2024 Jun;
12(9):1236-1251.
PMID: 38874582
CD70 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy for the treatment of both solid and liquid malignancies. However, the functionality of CD70-specific CAR T cells is...
7.
Daneels W, Van Parys A, Huyghe L, Rogge E, De Rouck S, Christiaen R, et al.
Exp Hematol Oncol
. 2024 Jun;
13(1):59.
PMID: 38831452
Type I interferon (IFN) is a potent antitumoral drug, with an important history in the treatment of hematologic malignancies. However, its pleiotropic nature leads to severe dose-limiting toxicities that blunt...
8.
Den Berghe T, Verberckmoes B, Kint N, Wallaert S, De Vos N, Algoet C, et al.
Insights Imaging
. 2024 Apr;
15(1):106.
PMID: 38597979
Objectives: Cytogenetic abnormalities are predictors of poor prognosis in multiple myeloma (MM). This paper aims to build and validate a multiparametric conventional and functional whole-body MRI-based prediction model for cytogenetic...
9.
Dreyling M, Fowler N, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, et al.
Blood
. 2024 Jan;
143(17):1713-1725.
PMID: 38194692
Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the third- or later-line setting. The primary analysis (median follow-up, 17 months) of the phase 2 ELARA trial...
10.
Richardson P, Facon T, Venner C, Bahlis N, Offner F, White D, et al.
EJHaem
. 2023 Nov;
4(4):995-1005.
PMID: 38024593
Deeper responses are associated with longer survival in multiple myeloma (MM); however, limited data exist on the impact of response kinetics on outcomes. We investigated progression-free survival (PFS) and duration...